Michal Geva

1.8k total citations
35 papers, 981 citations indexed

About

Michal Geva is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, Michal Geva has authored 35 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 20 papers in Cellular and Molecular Neuroscience and 13 papers in Neurology. Recurrent topics in Michal Geva's work include Pharmacological Receptor Mechanisms and Effects (22 papers), Genetic Neurodegenerative Diseases (12 papers) and Neurological disorders and treatments (10 papers). Michal Geva is often cited by papers focused on Pharmacological Receptor Mechanisms and Effects (22 papers), Genetic Neurodegenerative Diseases (12 papers) and Neurological disorders and treatments (10 papers). Michal Geva collaborates with scholars based in Canada, United States and Israel. Michal Geva's co-authors include Michael R. Hayden, Ilya Bezprozvanny, Iris Grossman, Rebecca Kusko, Jun Wu, Daniel A. Ryskamp, Abby Oehler, Stephen J. DeArmond, Kurt Giles and Duo Lü and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Brain.

In The Last Decade

Michal Geva

33 papers receiving 974 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michal Geva Canada 20 816 432 198 140 106 35 981
Hideyuki Takahashi United States 9 395 0.5× 273 0.6× 141 0.7× 124 0.9× 193 1.8× 17 856
Aaron Daub United States 8 534 0.7× 296 0.7× 313 1.6× 127 0.9× 119 1.1× 9 1.0k
Anna Sandebring Sweden 9 699 0.9× 296 0.7× 407 2.1× 89 0.6× 128 1.2× 13 1.1k
Zhiping Shao United States 12 442 0.5× 240 0.6× 91 0.5× 111 0.8× 113 1.1× 20 852
Fabrizio Pontarelli United States 12 514 0.6× 410 0.9× 379 1.9× 42 0.3× 183 1.7× 17 1.1k
José Aguilera Spain 20 530 0.6× 562 1.3× 395 2.0× 41 0.3× 73 0.7× 60 1.0k
Shilpa Ramaswamy United States 10 409 0.5× 441 1.0× 186 0.9× 23 0.2× 78 0.7× 13 762
Birgit Zucker Germany 8 737 0.9× 556 1.3× 173 0.9× 20 0.1× 46 0.4× 9 958
Marta Garcia‐Miralles Singapore 12 322 0.4× 240 0.6× 166 0.8× 34 0.2× 57 0.5× 21 515
Alfredo J. Miñano‐Molina Spain 15 459 0.6× 365 0.8× 42 0.2× 57 0.4× 122 1.2× 18 911

Countries citing papers authored by Michal Geva

Since Specialization
Citations

This map shows the geographic impact of Michal Geva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Geva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Geva more than expected).

Fields of papers citing papers by Michal Geva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Geva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Geva. The network helps show where Michal Geva may publish in the future.

Co-authorship network of co-authors of Michal Geva

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Geva. A scholar is included among the top collaborators of Michal Geva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Geva. Michal Geva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cruz-Herranz, Andrés, Kelly Chen, Katrin Spiegel, et al.. (2025). The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease. CNS Drugs. 39(5). 485–498. 3 indexed citations
3.
Geva, Michal, Y. Paul Goldberg, Melanie Leitner, et al.. (2025). Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 1–13.
4.
Tan, Andrew M., Michal Geva, Y. Paul Goldberg, et al.. (2025). Antidopaminergic medications in Huntington's disease. Journal of Huntington s Disease. 14(1). 16–29. 1 indexed citations
5.
Darpö, Börje, Michal Geva, Georg Ferber, et al.. (2023). Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose. Neurology and Therapy. 12(2). 597–617. 2 indexed citations
6.
Lenoir, Sophie, Hélène Vitet, Chiara Scaramuzzino, et al.. (2022). Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiology of Disease. 173. 105857–105857. 25 indexed citations
7.
Geva, Michal, Shaoming Wang, Noga Gershoni‐Emek, et al.. (2022). J11 Pridopidine exerts beneficial effects in preclinical models and in clinical trials via activation of the sigma-1 receptor, in a biphasic manner. A98.1–A98. 1 indexed citations
8.
Geva, Michal, Noga Gershoni‐Emek, Luana Naia, et al.. (2021). Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. Scientific Reports. 11(1). 21975–21975. 9 indexed citations
9.
Reilmann, Ralf, Anne Rosser, Sandra K. Kostyk, et al.. (2021). F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF). A36.1–A36. 1 indexed citations
10.
Naia, Luana, Philip T. T. Ly, Sandra I. Mota, et al.. (2021). The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models. Neurotherapeutics. 18(2). 1017–1038. 41 indexed citations
11.
McGarry, Andrew, Mika Leinonen, Karl Kieburtz, et al.. (2020). Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. Journal of Huntington s Disease. 9(4). 371–380. 24 indexed citations
12.
Francardo, Veronica, Michal Geva, Francesco Bez, et al.. (2019). Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics. 16(2). 465–479. 53 indexed citations
13.
Arbez, Nicolas, et al.. (2019). Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease. 129. 118–129. 48 indexed citations
14.
Smith-Dijak, Amy, et al.. (2019). Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 13. 209–209. 33 indexed citations
15.
Ionescu, Ariel, Tal Gradus, Topaz Altman, et al.. (2019). Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model. Cell Death and Disease. 10(3). 210–210. 72 indexed citations
16.
Ryskamp, Daniel A., Lili Wu, Jun Wu, et al.. (2018). Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiology of Disease. 124. 489–504. 57 indexed citations
17.
Kusko, Rebecca, Yoonjeong Cha, Renan Escalante-Chong, et al.. (2018). Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration. 13(1). 25–25. 35 indexed citations
18.
Ryskamp, Daniel A., Jun Wu, Michal Geva, et al.. (2016). The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease. 97(Pt A). 46–59. 105 indexed citations
19.
Lü, Duo, Kurt Giles, Zhe Li, et al.. (2013). Biaryl Amides and Hydrazones as Therapeutics for Prion Disease in Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics. 347(2). 325–338. 32 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideyuki Takahashi Breakdown of academic impact, for papers by Aaron Daub Breakdown of academic impact, for papers by Anna Sandebring Breakdown of academic impact, for papers by Zhiping Shao Breakdown of academic impact, for papers by Fabrizio Pontarelli Breakdown of academic impact, for papers by José Aguilera Breakdown of academic impact, for papers by Shilpa Ramaswamy Breakdown of academic impact, for papers by Birgit Zucker Breakdown of academic impact, for papers by Marta Garcia‐Miralles Breakdown of academic impact, for papers by Alfredo J. Miñano‐Molina
Rankless by CCL
2026